- Home
- JWEL vs ONVO Comparison
JWEL vs ONVO Comparison
Compare JWEL & ONVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JWEL
- ONVO
- Stock Information
- Founded
- JWEL 2012
- ONVO 2007
- Country
- JWEL China
- ONVO United States
- Employees
- JWEL N/A
- ONVO N/A
- Industry
- JWEL Other Consumer Services
- ONVO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- JWEL Consumer Discretionary
- ONVO Health Care
- Exchange
- JWEL Nasdaq
- ONVO Nasdaq
- Market Cap
- JWEL 6.1M
- ONVO 6.5M
- IPO Year
- JWEL 2021
- ONVO N/A
- Fundamental
- Price
- JWEL $3.05
- ONVO $0.39
- Analyst Decision
- JWEL
- ONVO
- Analyst Count
- JWEL 0
- ONVO 0
- Target Price
- JWEL N/A
- ONVO N/A
- AVG Volume (30 Days)
- JWEL 9.5K
- ONVO 243.5K
- Earning Date
- JWEL 12-19-2024
- ONVO 02-06-2025
- Dividend Yield
- JWEL 13.77%
- ONVO N/A
- EPS Growth
- JWEL N/A
- ONVO N/A
- EPS
- JWEL N/A
- ONVO N/A
- Revenue
- JWEL $160,009,293.00
- ONVO $103,000.00
- Revenue This Year
- JWEL N/A
- ONVO $59.08
- Revenue Next Year
- JWEL N/A
- ONVO $18.24
- P/E Ratio
- JWEL N/A
- ONVO N/A
- Revenue Growth
- JWEL N/A
- ONVO N/A
- 52 Week Low
- JWEL $1.00
- ONVO $0.32
- 52 Week High
- JWEL $3.71
- ONVO $1.74
- Technical
- Relative Strength Index (RSI)
- JWEL 54.41
- ONVO 47.81
- Support Level
- JWEL $3.01
- ONVO $0.34
- Resistance Level
- JWEL $3.20
- ONVO $0.51
- Average True Range (ATR)
- JWEL 0.25
- ONVO 0.06
- MACD
- JWEL 0.01
- ONVO -0.00
- Stochastic Oscillator
- JWEL 69.26
- ONVO 30.00
About JWEL Jowell Global Ltd.
Jowell Global Ltd is a cosmetics, health and nutritional supplements, and household products e-commerce platform. It operates under Online Direct Sales, Authorized Retail Store Distribution, Third-party Merchants, and Live streaming marketing sales channels. The company's major merchandise categories are Cosmetic products, Health and nutritional supplements, and Household Products.
About ONVO Organovo Holdings Inc.
Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.